Lupin Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin Limited has received approval from China's National Medical Products Administration (NMPA) for its Oseltamivir Phosphate Oral Suspension (6 mg/mL), developed in partnership with Yabao Pharmaceuticals. This is Lupin's first product to enter the Chinese market, marking a significant milestone in its global expansion strategy. The drug is approved for treatment of influenza A and B in patients as young as 2 weeks of age, and for prevention in individuals aged 1 year and above. The approval leverages Yabao's strong paediatric medicine presence in China, with Yabao holding manufacturing sites approved by the US FDA and a European agency.
This approval gives Lupin access to one of the world's largest pharmaceutical markets and diversifies its geographic revenue base. The paediatric-focused flu treatment fills an important market need and could become a meaningful revenue contributor over time, though near-term financial impact will depend on launch timelines.